New drug for MTAP-deleted solid tumors
Part of Cancer clinical trials.
This trial tests a new experimental drug (HSK41959) for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and effective for tumors that no longer respond to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must be advanced or have spread, and you must have tried standard treatments that didn't work or caused bad side effects.
- Your tumor must be missing both copies of a gene called MTAP (a genetic test will confirm this).
- You must be able to do daily activities with little to no help (ECOG score 0 or 1).
- You cannot have had certain other cancer treatments within the last few weeks, or ever taken a drug that targets PRMT5 or MAT2A.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called HSK41959 combined with standard cancer therapy for people whose tumors have a specific genetic change (MTAP deletion). The goal is to see if the combination is safe and works better against advanced solid tumors, including non-small cell lung cancer and pancreatic cancer.
This study tests a new drug called GS-2426 for people with advanced solid tumors that have a specific genetic change called MTAP deficiency. It may be an option if other treatments have stopped working or are not available.
This trial tests a new drug, Navlimetostat (BMS-986504), for people with advanced solid tumors that have a specific genetic change called MTAP deletion or loss. It looks at safety, side effects, and how the drug works in the body.
This trial tests an investigational drug called HS-10587 for people with advanced solid tumors that have a specific genetic change (MTAP deletion) and have not responded to standard treatments. The goal is to see if the drug can shrink tumors or slow their growth.
This study tests a new oral drug called ISM3412 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug called BAY 3713372 in people with solid tumors that have a specific genetic change called MTAP deletion. The drug targets a process inside cells that may help stop tumor growth.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.